Genzyme Corp. has announced that it will buy Bioenvision, Inc. for approximately $345 million in cash. The purchase, which has unanimous support from Bioenvision’s board, will enhance Genzyme’s oncology business by yielding exclusive, worldwide rights to clofarabine. The two companies co-developed clofarabine in Europe, where Bioenvision currently markets the product for the treatment of acute lymphoblastic leukemia (ALL) in relapsed and refractory pediatric patients. Clofarabine is ...